Playing Health Care Reform w/ Genetics Stocks

Thursday, 5 Mar 2009 | 4:41 PM ET

It's still not clear what, if any, reform is going to come to U.S. health care, but Miller Tabak's Les Funtleyder is ready to play it.

"It's basically a sentiment call, because valuations are pretty attractive in the sector," he told CNBC. "There are some companies we like in the genetics space, which would benefit by increased NIH [National Institutes of Health] spending."

Although he has his game plan drawn up, he said he's reluctant to move into the market until mid-April.


The names on his list are Illumina, Luminex, and Genoptix.

Smart Money: Health Care Reform Plays
Insight on how President Obama's health care reform summit will impact the sector and what the smart plays are, with Joel Sendek, Lazard Capital Markets and Les Funtleyder, Miller Tabak


Neither Funtleyder, his family, nor his firm owns shares in, or has any business relationship with, Illumina, Luminex and Genoptix.


  Price   Change %Change